Computational and Mathematical Methods in Medicine comparison of logP methods on more than 96,000 com- pounds,” Journal of Pharmaceutical Sciences, vol. 98, no. 3, pp. 861–893, 2009. [34] M. Yazdanian, S. L. Glynn, J. L. Wright, and A. Hawi, “Corre- lating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds,” Pharmaceutical Research, vol. 15, no. 9, pp. 1490–1494, 1998. [35] R. G. Jain, E. S. Furﬁne, L. Pedneault, A. J. White, and J. M. Lenhard, “Metabolic complications associated with antiretro- viral therapy,” Antiviral Research, vol. 51, no. 3, pp. 151–177, 2001. [36] S. K. Gan, K. Samaras, A. Carr, and D. Chisholm, “Anti- retroviral therapy, insulin resistance and lipodystrophy,” Dia- betes, Obesity and Metabolism, vol. 3, no. 2, pp. 67–71, 2001. [37] M. J. Glesby, “Toxicities and adverse ﬁndings associated with protease inhibitors,” in Protease Inhibitors in AIDS Therapy, R. C. Ogden and C. W. Flexner, Eds., pp. 237–256, Marcel Dekker, Inc., New York, NY, USA, 2001. [38] P. A. Pham and C. Flexner, “Emerging antiretroviral drug interactions,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 2, pp. 235–239, 2011. [39] D. Wang, B. Larder, A. Revell et al., “A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy,” Artiﬁcial Intelligence in Medicine, vol. 47, no. 1, pp. 63–74, 2009. [40] O. Krakovska and L. M. Wahl, “Optimal drug treatment regimens for HIV depend on adherence,” Journal of Theoretical Biology, vol. 246, no. 3, pp. 499–509, 2007. [41] S. Hongzong, Y. Shuping, Z. Kejun, F. Aiping, D. Yun-Bo, and H. Zhide, “Quantitative structure activity relationship study on EC50 of anti-HIV drugs,” Chemometrics and Intelligent Laboratory Systems, vol. 90, no. 1, pp. 15–24, 2008. [42] B. Testa, P. Crivori, M. Reist, and P. A. Carrupt, “The inﬂuence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples,” Perspectives in Drug Discovery and Design, vol. 19, pp. 179–211, 2000. [43] J. W. Nichols, M. Bonnell, S. D. Dimitrov, B. I. Escher, X. Han, and N. I. Kramer, “Bioaccumulation assessment using predictive approaches,” Integrated Environmental Assessment and Management, vol. 5, no. 4, pp. 577–597, 2009. [44] C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate sol- ubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 23, no. 1–3, pp. 3–25, 1997. [45] W. B. Neely, D. R. Branson, and G. E. Blau, “Partition coeﬃcient to measure bioconcentration potential of organic chemicals in ﬁsh,” Environmental Science and Technology, vol. 8, no. 13, pp. 1113–1115, 1974. [46] S. Dimitrov, T. Pavlov, D. Nedelcheva et al., “A kinetic model for predicting biodegradation,” SAR and QSAR in Environmental Research, vol. 18, no. 5-6, pp. 443–457, 2007. [47] S. D. Dimitrov, N. C. Dimitrova, J. D. Walker, G. D. Veith, and O. G. Mekenyan, “Predicting BCFs of highly hydrophobic chemicals: eﬀects of molecular size,” Pure and Applied Chem- istry, vol. 74, no. 10, pp. 1823–1830, 2002. [48] P. Howard, W. Meylan, D. Aronson et al., “A new biodegra- dation prediction model speciﬁc to petroleum hydrocarbons,” Environmental Toxicology and Chemistry, vol. 24, no. 8, pp. 1847–1860, 2005. 9